More recently, both the SUMMIT and ExteNET trials have shown the combination of neratinib, an irreversible pan-HER TKI, with endocrine therapies including fulvestrant and physicians’ choice of SERM/AI to have efficacy in HER2+/ER+ breast cancer patients [13,14]. This evidence concerns the gene ESR1 and breast carcinoma.